A systematic review of patient outcomes for primary pediatric flexor tendon repairs

对儿童屈肌腱原发性修复术患者预后进行系统评价

阅读:1

Abstract

BACKGROUND: Literature on pediatric flexor tendon repairs remains sparse. Given the various repair techniques and rehabilitation protocols available, the aim of this systematic review is to investigate outcomes of primary pediatric flexor tendon repairs. METHODS: MEDLINE, Embase, PubMed, and Cochrane Central Register of Controlled Trials databases were searched from inception to June 2022 in concordance with PRISMA guidelines. Studies were included if patients were under the age of 18, sustained a flexor tendon injury repaired primarily, and had documented functional outcomes. Quality assessment was completed using the Newcastle-Ottawa Scale. The study was registered with PROSPERO (CRD42018089089). RESULTS: This study includes 20 articles representing 577 patients with 748 injured digits, most frequently injured by a laceration from glass. The number of tendon injuries in zones I, II, III, IV, and V were 78, 431, 62, 2, and 19, respectively. In total, 594 FDP, 374 FDS, and 77 FPL tendons were lacerated. Concurrent digital nerve injuries occurred in 251 digits. Time of repair was 15 ​h-187 days post-injury, most commonly via the modified Kessler (n ​= ​266 digits) and Kessler (n ​= ​162 digits). Post-operatively, 170 patients were immobilized and 261 patients underwent early active (n ​= ​96) or passive (n ​= ​165) protocols. Functional outcomes were reported in 466 digits (excellent ​= ​306, good ​= ​132, fair ​= ​19, and poor ​= ​9, per the respective assessment tool used). There were 15 tendon ruptures. CONCLUSIONS: Despite heterogeneity in both operative and post-operative protocols, there is low level evidence that low complication rates and good outcomes are expected following primary repair of pediatric flexor tendons.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。